Global Omalizumab Monoclonal Antibody Biosimilars Market Size Likely to Grow at a CAGR of 13.39% By 2035

The worldwide omalizumab monoclonal antibody biosimilars market size was approximately USD 1.82 billion in 2025 and is expected to reach approximately USD 2.06 billion in 2026 and will grow to nearly USD 6.40 billion by 2035 and would witness a CAGR of 13.39% between the forecast period of 2026 to 2035.

Omalizumab Monoclonal Antibody Biosimilars Market  Revenue and Trends

The Omalizumab Monoclonal Antibody Biosimilars market is gaining traction as more and more health providers and consumers seek for affordable substitutes to biologics for treating allergies. Especially as the utility of Xolair is proven for treating allergic asthma, chronic spontaneous urticaria and other allergic diseases, and patent expiries in biologics encourage for the entrance of biosimilars in the market. Pharmaceutical companies are focusing on biotechnology to create low-cost alternatives that have the same therapeutic benefits as expensive biologics, while the favorable government policies, increasing patient prevalence, expanding healthcare expenses and growing awareness among doctors and patients will fuel the Omalizumab Monoclonal Antibody Biosimilars market as the global demand for cheaper biological alternatives grows.

What are the main growth drivers of Omalizumab Monoclonal Antibody Biosimilars Market?

Growing demand for low-cost biologic therapies to treat chronic allergic conditions like allergic asthma, and chronic spontaneous urticaria is driving the Omalizumab Monoclonal Antibody Biosimilars market. As patents of reference drugs like Xolair are expiring, biosimilar manufacturers are entering the market by providing cheaper substitutes to making advanced therapies accessible to larger population. Increasing incidences of allergic and immunological diseases and growing cost burden associated with original biologics are prompting medical practitioners and patients towards biosimilars and favorable regulatory routes for approvals and growing confidence regarding the safety and effectiveness of biosimilars are also helping in driving the demand for Omalizumab Monoclonal Antibody Biosimilars market.

In addition, development in the manufacturing processes of biopharmaceutical and increased investment in the R&D leading to enhancement in the quality and scalability of biosimilars. The healthcare expenditure in the countries, supportive government policies for cost effective medical treatments and increased coverage for the insurance schemes and for making the access for the biologic treatments easier in developing countries are further increasing the demand for Omalizumab Monoclonal Antibody Biosimilars market. The entire development of the healthcare sector along with value-based care and sustainable treatment options is contributing to the long-term positive growth trajectory for the Omalizumab Monoclonal Antibody Biosimilars market.

Segment Insight

By Product Type

The subcutaneous injection is expected to hold a largest market share owing to the ease of administration and the acceptance among patients, and its common use in outpatients, especially for treatment of allergic asthma and chronic spontaneous urticaria. The intravenous injection is expected to hold a substantial market share which mainly exists in the regulated clinical environment requiring closely observation, and its increasing application in outpatient settings owing to increased adoption of self-administration practice and reduced visits to hospital. The adoption of self-administration practice and the less dependence on visits to hospital are likely to support the trend.

By Application

Asthma is estimated to account for the largest share of the market owing to the high incidence rate of allergic asthma in the world and the growing prescription rate of biologics for treating asthma of severe extent, like Xolair. Chronic idiopathic urticaria holds a substantial market share as the increasing awareness and diagnosis of allergic chronic skin disease. The segment of nasal polyps is expected to witness growth at a significant pace as omalizumab is gaining approval for more and more applications, and the other applications mainly comprising of emerging allergic and immune diseases are expected to witness a moderate growth rate owing to increase in research and off-label application of the drug.

By Distribution Channel

Hospital pharmacies hold a majority market share of the Omalizumab monoclonal antibody biosimilars market as special prescriptions and controlled administration is required. The retail pharmacies are also holding a significant market share due to increased accessibility of the biologic drug along with increased preference of long-term therapy for treating the chronic illness. The market share of the online pharmacies is also estimated to rise with increase in digitalization of access to specialty drugs and increased efficiency of services. The other distribution channels are also expected to witness a growth at a steady rate.

By Region

The North America region accounts for the largest market share owing to the advanced healthcare infrastructure present and the widespread adoption of biologics and supportive government policies for approval of biosimilars and also the increased acceptance of treatment options. Europe accounts for a considerable market share owing to the favorable government policies supporting the use of biosimilars and reduction in the healthcare expenses. The market of the Asia-Pacific region is expected to witness the highest growth owing to increasing healthcare expenses, a large number of occurrences of allergic disease, and an increase in access to the latest treatment, particularly India and China. Middle East & Africa and Latin America are expected to witness a moderate market share with the increase in healthcare infrastructure and the demand for more affordable biologics.

Report Scope

Recent Developments

• On March 2024, Biocon Limited updated on progress on its biosimilars portfolio, including development and commercialization of monoclonal antibody biosimilars, such as omalizumab, focusing on improving global market access, collaborations and increasing manufacturing capacity to develop affordable therapies for allergy conditions and affordable biologics globally.

List of the prominent players in the Omalizumab Monoclonal Antibody Biosimilars Market:

• Roche Holding AG

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Mylan N.V.

• Pfizer Inc.

• Amgen Inc.

• Samsung Bioepis Co. Ltd.

• Celltrion Healthcare Co. Ltd.

• Biocon Limited

• Sandoz International GmbH

• Dr. Reddy's Laboratories Ltd.

• Fresenius Kabi AG

• Stada Arzneimittel AG

• Coherus BioSciences Inc.

• Apotex Inc.

• Hoffmann-La Roche Ltd.

• Merck & Co. Inc.

• Lupin Limited

• Zydus Cadila

• Intas Pharmaceuticals Ltd.

• Others

The Omalizumab Monoclonal Antibody Biosimilars Market is segmented as follows:

By Product Type

• Subcutaneous Injection

• Intravenous Injection

By Application

• Asthma

• Chronic Idiopathic Urticaria

• Nasal Polyps

• Others

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America